guardian pharmacy services inc - GRDN

GRDN

Close Chg Chg %
37.53 -1.00 -2.66%

Closed Market

36.53

-1.00 (2.66%)

Volume: 435.14K

Last Updated:

Mar 25, 2026, 3:59 PM EDT

Company Overview: guardian pharmacy services inc - GRDN

GRDN Key Data

Open

$37.61

Day Range

36.27 - 37.99

52 Week Range

19.01 - 38.09

Market Cap

$2.38B

Shares Outstanding

63.32M

Public Float

22.49M

Beta

0.86

Rev. Per Employee

N/A

P/E Ratio

48.32

EPS

$0.79

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

518.37K

 

GRDN Performance

1 Week
 
2.47%
 
1 Month
 
8.92%
 
3 Months
 
18.74%
 
1 Year
 
81.14%
 
5 Years
 
N/A
 

GRDN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About guardian pharmacy services inc - GRDN

Guardian Pharmacy Services, Inc. engages in the provision of client service and resident care to long-term care communities. It offers assisted living and skilled nursing, group homes, behavioral health and organizations that serve individuals with intellectual and developmental disabilities. The company was founded by Fred Burke, David Morris, and Kendall Forbes on July 21, 2003 and is headquartered in Atlanta, GA.

GRDN At a Glance

Guardian Pharmacy Services, Inc.
300 Galleria Parkway SE
Atlanta, Georgia 30339
Phone 1-404-810-0089 Revenue 1.45B
Industry Drugstore Chains Net Income 49.22M
Sector Retail Trade 2025 Sales Growth 17.932%
Fiscal Year-end 12 / 2026 Employees 3,600
View SEC Filings

GRDN Valuation

P/E Current 48.315
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 38.696
Price to Sales Ratio 1.315
Price to Book Ratio 9.26
Price to Cash Flow Ratio 19.00
Enterprise Value to EBITDA 17.042
Enterprise Value to Sales 1.309
Total Debt to Enterprise Value 0.024

GRDN Efficiency

Revenue/Employee 402,412.50
Income Per Employee 13,671.944
Receivables Turnover 14.257
Total Asset Turnover 3.782

GRDN Liquidity

Current Ratio 1.379
Quick Ratio 1.109
Cash Ratio 0.408

GRDN Profitability

Gross Margin 19.469
Operating Margin 6.138
Pretax Margin 5.068
Net Margin 3.397
Return on Assets 12.85
Return on Equity 28.252
Return on Total Capital 19.65
Return on Invested Capital 24.078

GRDN Capital Structure

Total Debt to Total Equity 21.736
Total Debt to Total Capital 17.855
Total Debt to Total Assets 10.382
Long-Term Debt to Equity 16.375
Long-Term Debt to Total Capital 13.452
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Guardian Pharmacy Services Inc - GRDN

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
908.91M 1.05B 1.23B 1.45B
Sales Growth
+14.75% +15.10% +17.42% +17.93%
Cost of Goods Sold (COGS) incl D&A
730.50M 846.54M 993.45M 1.17B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
16.56M 18.23M 19.77M 22.34M
Depreciation
13.20M 15.17M 16.47M 18.68M
Amortization of Intangibles
3.37M 3.07M 3.30M 3.66M
COGS Growth
+14.47% +15.88% +17.35% +17.43%
Gross Income
178.40M 199.65M 234.96M 282.04M
Gross Income Growth
+15.90% +11.91% +17.69% +20.04%
Gross Profit Margin
+19.63% +19.08% +19.13% +19.47%
2022 2023 2024 2025 5-year trend
SG&A Expense
126.41M 158.71M 297.88M 193.13M
Research & Development
- - - -
-
Other SG&A
126.41M 158.71M 297.88M 193.13M
SGA Growth
+2.13% +25.54% +87.69% -35.17%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 16.21M
-
EBIT after Unusual Expense
51.99M 40.95M (62.92M) 72.70M
Non Operating Income/Expense
(403.00K) (367.00K) (279.00K) 1.39M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.93M 2.86M 3.28M 665.00K
Interest Expense Growth
+17.65% +48.44% +14.66% -79.71%
Gross Interest Expense
1.93M 2.86M 3.28M 665.00K
Interest Capitalized
- - - -
-
Pretax Income
49.66M 37.72M (66.48M) 73.42M
Pretax Income Growth
+75.32% -24.05% -276.24% +210.45%
Pretax Margin
+5.46% +3.61% -5.41% +5.07%
Income Tax
- - 4.56M 24.46M
-
Income Tax - Current - Domestic
- - 3.85M 21.39M
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - 701.00K 3.07M
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
49.66M 37.72M (71.03M) 48.96M
Minority Interest Expense
14.24M 13.82M 39.01M (261.00K)
Net Income
35.42M 23.90M (110.05M) 49.22M
Net Income Growth
+117.12% -32.52% -560.41% +144.73%
Net Margin Growth
+3.90% +2.28% -8.96% +3.40%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
35.42M 23.90M (110.05M) 49.22M
Preferred Dividends
- - - -
-
Net Income Available to Common
35.42M 23.90M (110.05M) 49.22M
EPS (Basic)
0.5704 0.3849 -1.7388 0.7889
EPS (Basic) Growth
+117.13% -32.52% -551.75% +145.37%
Basic Shares Outstanding
62.09M 62.09M 63.29M 62.39M
EPS (Diluted)
0.5704 0.3849 -1.7388 0.7776
EPS (Diluted) Growth
+117.13% -32.52% -551.75% +144.72%
Diluted Shares Outstanding
62.09M 62.09M 63.29M 63.30M
EBITDA
68.55M 59.18M (43.15M) 111.25M
EBITDA Growth
+46.86% -13.67% -172.91% +357.83%
EBITDA Margin
+7.54% +5.66% -3.51% +7.68%

Snapshot

Average Recommendation BUY Average Target Price 35.00
Number of Ratings 4 Current Quarters Estimate 0.243
FY Report Date 03 / 2026 Current Year's Estimate 1.235
Last Quarter’s Earnings 0.37 Median PE on CY Estimate N/A
Year Ago Earnings 1.07 Next Fiscal Year Estimate 1.358
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 0.24 0.27 1.24 1.36
High Estimates 0.25 0.27 1.27 1.41
Low Estimate 0.24 0.26 1.20 1.32
Coefficient of Variance 2.06 2.18 2.52 3.03

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Guardian Pharmacy Services Inc - GRDN

Date Name Shares Transaction Value
Mar 4, 2026 David Morris See Remarks; Director 442,327 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Kendall Forbes See Remarks 799,928 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Cardinal Equity Partners LLC Director 471,057 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Fred Burke See Remarks; Director 1,298,826 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Pharmacy Investments, L.L.C. Director 1,413,940 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Bindley Capital Partners I LLC Director 6,100,176 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Guardian Pharmacy Services Inc in the News